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Abstract. Polymorphisms of the endothelial nitric oxide 
synthase (enoS) gene have been implicated in various 
diseases associated with cardiovascular risk factors, but little 
is known regarding the risks of ischemic stroke (iS) in patients 
with diabetes mellitus (dM). in this study, we evaluated the 
genotypes and haplotypes of three enoS polymorphisms 
(-786T>c, 4a4b and 894G>T) in a Korean population of 223 
IS patients and 206 controls classified into four groups: healthy 
subjects, type 2 dM patients without iS, iS patients without 
type 2 dM and iS patients with type 2 dM. The genotype 
frequency of 4a4b in the controls with type 2 dM differed 
significantly from that in the controls without DM (4b4b vs. 
4a4b; or=2.769; 95% ci 1.233-6.220). and the frequency of the 
-786c-4a-894G haplotype was higher in the controls with dM 
compared to the controls without dM (P=0.040). additionally, 
the -786c-4b-894G haplotype was more common in the cases 
with dM than in the controls without type 2 dM (P=0.034). 
Our findings suggest that the eNOS 4a allele-associated geno-
type and haplotype is a risk factor for type 2 dM, and that the 
-786c-4b-894G haplotype is a risk factor for iS with dM.
Introduction
ischemic stroke (iS) is a leading cause of death and disability 
in the developed world, and is known to be a multi-factorial 
disorder caused by a combination of genetic and environ-
mental risk factors (1-2). For example, type 2 diabetes mellitus 
(DM) is associated with a 2- to 5-fold increased risk for first or 
recurrent iS (3-5). The mechanisms behind the association are 
myriad, and include the effects of hyperglycemia on vascular 
tissues and coagulation, as well as aberrations in blood 
pressure regulation, endothelial function, lipid metabolism, 
vascular inflammation, lipid metabolism and smooth muscle 
cell proliferation.
nitric oxide (no) is produced from l-arginine by endothe-
lial nitric oxide synthase (enoS) and is involved in vessel 
homeostasis by inhibiting vascular smooth muscle contrac-
tion and growth, platelet aggregation and leukocyte adhesion 
to the endothelium (6-8). endothelial dysfunction is related 
to alternating vascular reactivity and vasospasm by dimin-
ished no production leading to the impaired vasodilation of 
arteries, and is known to be associated with cardiovascular 
risk factors such as stroke, type 2 dM and atherosclerosis 
(9-11). Moreover, since abnormalities in the activity of enoS 
affecting the level of plasma NO have been identified, the 
enoS gene is a possible candidate gene for susceptibility to 
stroke (12). Several single nucleotide polymorphisms (SnPs) in 
this gene have been identified, of which three polymorphisms 
(-786T>c located in the promoter of the enoS gene, a 27-bp 
repeat polymorphism in intron 4 and 894G>T in exon 7) have 
been shown to be associated with iS (13-17). Most of these 
studies examined the association of these SnPs with dM or 
iS individually; little is known regarding the effect of SnPs 
in the enoS gene on the susceptibility to iS of patients with 
dM. Here, we evaluated the enoS genotype and haplotype 
distribution of the most relevant polymorphisms (-786T>c, 
4a4b and 894G>T) in a Korean population classified into four 
groups: healthy subjects, type 2 dM patients without iS, iS 
patients without type 2 dM, and iS patients with type 2 dM.
Materials and methods
Subjects. The study subjects included 223 iS patients 
(including 67 type 2 dM patients) and 206 control subjects 
without iS (including 36 type 2 dM patients) (Table i). The 
iS patients were recruited upon enrollment at the department 
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of neurology at Bundang cHa General Hospital between 
november 2003 and June 2005 by consecutive referral. iS was 
defined as a stroke, i.e., a clinical syndrome characterized by 
rapidly developing clinical symptoms and signs of focal and at 
times global loss of brain function, with evidence of a cerebral 
infarction in the clinically relevant area of the brain by a brain 
imaging study. 
The diagnosis of IS was made when neurologic deficits 
were accompanied by corresponding abnormal magnetic 
resonance imaging (MRI) findings of the brain, which were 
interpreted by two independent experienced neurologists. 
an iS patient was excluded when researchers did not reach 
agreement. Patients with cerebral hemorrhage were excluded 
in advance. examinations were performed with a 1.5-T super-
conducting magnetic system (Siemens Magnetom Symphony, 
erlangen, Germany) and the whole brain was scanned with a 
slice thickness of 7 mm and a 2-mm interslice gap, producing 
16 axial images.
dM was diagnosed when a patient had a high fasting 
plasma glucose ≥126 mg/dl (18) or had been treated with oral 
hypoglycemic agents or insulin. Hypertension was defined as 
a systolic pressure >140 mmHg and/or a diastolic pressure 
>90 mmHg on more than one occasion, according to the Joint 
national committee (Jnc 7) report guidelines (19), and the 
current taking of anti-hypertensive medications. Smokers 
were defined as those who were smoking at the time of exami-
nation. 
as controls, gender- and age-matched healthy subjects 
were selected from individuals who presented at the Bundang 
cHa General Hospital for a health examination during the 
same period. These individuals had no history of myocar-
dial infarction or cerebrovascular disease. The institutional 
review Board of Bundang cHa General Hospital approved 
this genetic study in october 2003. all patients and controls 
were Korean and gave their informed consent prior to enroll-
ment in the study.
Genetic analyses. Genomic dna was extracted from periph-
eral blood leukocytes using the G-deX blood extraction kit 
(intron inc., Seongnam, Korea). nucleotide changes were 
determined by polymerase chain reaction (Pcr)-restriction 
fragment length polymorphism analyses using the isolated 
genomic dna as a template. Pcr for the -786T>c polymor-
phism was performed using the following primers: 5'-aTG 
cTc cca cca GGG caT ca-3' (forward) and 5'-GTc cTT 
Gaa TcT Gac aTT aGG G-3' (reverse). dna was ampli-
fied by 35 cycles of denaturing at 94˚C for 30 sec, annealing 
at 51˚C for 40 sec and extension at 72˚C for 40 sec. The PCR 
products were detected by gel electrophoresis after incuba-
tion with a restriction endonuclease (NgOMiV; new england 
Biolabs, Beverly, MA, USA) at 37˚C for 16 h. 
The primer sequences used to detect the enoS 4a4b poly-
morphism were 5'-aGG ccc TaT GGT aGT Gcc TTT-3' 
(forward) and 5'-TcT cTT TaG TGc TGT GGT cac-3' 
(reverse). DNA was amplified by 35 cycles of denaturing at 
94˚C for 1 min, annealing at 49˚C for 40 sec and extension 
at 72˚C for 40 sec. The PCR products were visualized by gel 
electrophoresis. The primers used to detect the 894G>T poly-
morphism were 5'-caT GaG GcT caG ccc caG aac-3' 
(forward) and 5'-aGT caa Tcc cTT TGG TGc Tca c-3' 
(reverse). Pcr reactions were run for 35 cycles as follows: 
95˚C for 45 sec, 63˚C for 45 sec and 72˚C for 45 sec. The 
products were digested with a restriction endonuclease (Mboi; 
New England Biolabs) at 37˚C for 16 h and detected by gel 
electrophoresis.
Statistical analysis. clinical characteristics were compared 
using the Student's unpaired t-test. The distribution of geno-
types for each polymorphism was assessed for deviation from 
Hardy-Weinberg equilibrium, and differences in genotype 
frequency and allele frequency between groups were assessed 
using χ2 tests. a value of P<0.05 was considered statistically 
significant. StatsDirect Statistical Software version 2.4.4 
(Statsdirect ltd., altrincham, uK) was used to calculate the 
adjusted odds ratio (aor) and 95% ci. Haplotype analysis 
was performed using SNPAlyze version 5.1 Standard/Pro 
(dynacom co., ltd, Yokohama, Japan). 
Results
Table i shows the demographic and clinical characteristics 
of the subjects enrolled in the study. Both iS patients and 
controls were sub-grouped according to type 2 dM status. no 
significant differences in gender or age existed between the 
sub-groups. Smoking status did not differ between the sub-
groups, but hyperlipidemia was higher in the controls and in 
Table i. demographic and clinical characteristics of ischemic stroke patients and controls.
characteristics Subjects without iS Subjects with iS
 ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------
 controls Subjects P-value controls Subjects P-value
 (no dM; n=170) (with dM; n=36)  (no dM; n=156) (with dM; n=67)
Male (%) 84 (49.4) 23 (63.9)   0.142   92 (59.0) 37 (55.2) 0.658
age (years) 59.89±0.85 61.28±1.82   0.495 61.09±0.91 63.58±1.24 0.123
Smokers (%) 16   (9.4)   7 (19.4)   0.140   23 (14.7)   9 (13.4) 1.000
Hyperlipidemia (%) 19 (11.2) 15 (41.7) <0.0001   46 (29.5) 36 (53.7) 0.001
Hypertension (%) 82 (48.2) 25 (69.4)   0.027 107 (68.6) 48 (71.6) 0.751
iS, ischemic stroke; dM, diabetes mellitus.
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the iS with dM group (P<0.05). in addition, hypertension was 
significantly higher in the control group with DM compared 
to the control group without dM (P=0.027), in contrast to the 
comparison of the iS sub-groups. 
Three enoS gene polymorphisms (-786T>c, 4a4b and 
894G>T) were genotyped. The genotype frequencies of all 
polymorphisms were in accordance with Hardy-Weinberg 
equilibrium in the cases and control groups (data not shown). 
as shown in Table ii, the genotype frequency of 4a4b in 
controls with DM was significantly different from that in 
the controls without dM (4b4b vs. 4a4b; or=2.769; 95% ci 
1.233-6.220). no predisposition to dM was shown with the 
-786T>c and 894G>T polymorphisms in either the controls 
or iS cases.
The haplotype analysis of the three polymorphisms was 
examined in the four groups (Table iii). The -786T-4a-894G 
haplotype ranged from 79 to 83% in all sub-groups, and was the 
most common form observed in this study. The frequency of 
the -786c-4a-894G haplotype was higher in the controls with 
dM than in the controls without dM (P=0.040). additionally, 
the -786c-4b-894G haplotype was more common in the cases 
with dM than in the controls without dM (P=0.034).
Discussion
no is a molecule with pluripotent effects in various tissues 
and plays an important role in cerebrovascular regulation. 
no is produced by enoS, and its polymorphisms have 
Table ii. endothelial nitric oxide synthase polymorphisms in ischemic stroke patients and controls with diabetes mellitus.
Genotype controls without iS (n=206) cases with iS (n=223)
 -------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------
 no dM With dM or (95% ci) no dM or (95% ci) With dM or (95% ci)
enoS -786T>c
TT 145 (85.3) 26 (72.2)  1.0 (-) 129 (82.7)  1.0 (-) 57 (85.1)  1.0 (-)
Tc   25 (14.7) 10 (27.8) 2.231   27 (17.3) 1.214 10 (14.9) 1.018
   (0.959-5.188)  (0.671-2.198)  (0.460-2.253)
cc 0 (0.0) 0 (0.0) - 0 (0.0) - 0 (0.0) -
enoS 4a4b
4b4b 144 (84.7) 24 (66.7)  1.0 (-) 129 (82.7)  1.0 (-) 57 (85.1)  1.0 (-)
4a4b   26 (15.3) 12 (33.3) 2.769   27 (17.3) 1.159 10 (14.9) 0.972
   (1.233-6.220)  (0.643-2.089)  (0.440-2.144)
4a4a 0 (0.0) 0 (0.0) - 0 (0.0) - 0 (0.0) -
enoS 894G>T
GG 135 (79.4) 33 (91.7)  1.0 (-) 126 (80.8)  1.0 (-) 58 (86.6)  1.0 (-)
GT   35 (20.6) 3 (8.3) 0.351   29 (18.6) 0.888   9 (13.4) 0.599
   (0.102-1.211)  (0.513-1.537)  (0.270-1.325)
TT 0 (0.0) 0 (0.0) -   1 (0.6) 3.213 0 (0.0) -
     (0.130-79.67)
eNOS, endothelial nitric oxide synthase; IS, ischemic stroke; DM, diabetes mellitus. Values in bold are significant. 
Table iii. enoS haplotypes in ischemic stroke patients and controls with diabetes mellitus.
Haplotype controls (no dM) controls (with dM) cases (no dM) cases (with dM) p1 p2 p3
T-4b-G 0.821 0.792 0.815 0.835 0.555 0.821 0.719
T-4b-T 0.099 0.042 0.086 0.067 0.119 0.559 0.272
c-4a-G 0.067 0.139 0.064 0.052 0.040 0.898 0.536
T-4a-G 0.006 0.028 0.011 0.023 0.085 0.482 0.104
c-4b-G 0.003 5.91e-11 0.011 0.023 0.644 0.216 0.034
c-4a-T 0.004 0.004 0.009 0.0 0.606 0.376 -
c-4b-T 3.61e-77 0.000 0.002 0.0 - 0.398 -
T-4a-T 2.923e-87 0.000 0.002 0.0 - 0.398 -
p1, controls without dM vs. controls with dM; p2, controls without dM vs. cases without dM; p3, controls without dM vs. cases with dM. 
eNOS, endothelial nitric oxide synthase; IS, ischemic stroke; DM, diabetes mellitus. Values in bold are significant. 
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been reported to be associated with the development of 
iS. However, the results of studies on the subject have been 
inconsistent (15,16,20). in addition, dM is associated with 
a substantially increased risk of total and most subtypes of 
stroke (21). To date, most association studies have focused on 
the effect of polymorphisms in the enoS gene for iS alone 
(20). Since dM is one of the known predisposing factors to iS, 
we hypothesized that an eNOS polymorphism or haplotype is 
associated with susceptibility to iS in patients with dM. The 
results of this association study with four groups demonstrate 
that the frequency of genotypes and haplotypes with the 4a 
allele in intron 4 is associated with the status of dM, but not 
with iS. additionally, the frequency of -786c-4b-894G in 
the patients with DM differed significantly from that in the 
controls without dM. 
Song et al (22) studied genotype-specific influences on 
NOS protein concentration and enzyme activity in vitro, and 
showed that protein expression and enzyme activity were lower 
in the 4a4b genotype than in the 4b4b genotype. The authors 
suggested that this effect may be mediated by the -786T>c 
polymorphism in the promoter region, since the 4a allele is 
highly linked to the -786c allele in the Korean population 
(22,23). Consistent with this, in the present study significant 
differences in the enoS 4a allele and in -786c-4a-894G 
haplotype distributions were observed in controls with type 2 
dM compared to those without. 
in agreement with the present study, ohtoshi et al (24) 
showed that type 2 diabetic patients with the -786c allele 
had a lower plasma no concentration than non-diabetic 
subjects, and implied that the -786T>c polymorphism impairs 
endothelial no production, resulting in a decrease in insulin-
mediated glucose uptake due to impaired vasodilatation and 
poor glycaemic control (24). However, the study did not find 
a significant association between the -786T>C polymorphism 
and type 2 dM in the Japanese population studied. We too 
found no association between the -786T>c genotype frequen-
cies of iS patients with or without dM and those of the 
controls, but the frequency of the -786c-4b-894G haplotype 
was significantly different in the IS cases with DM compared 
to the controls. 
This finding suggests that the -786C allele is not an 
independent predisposing factor for iS, but rather may have 
an additive effect with another allele on the predisposition of 
patients with dM to iS. However, to validate this observation, 
a large sample size will be required to clearly demonstrate the 
effect of two polymorphisms in this group, since the frequency 
of the haplotype was rare in our population. This is the first 
report to identify an association between enoS polymor-
phisms and iS in patients with type 2 dM, even though enoS 
polymorphisms for type 2 dM complications are available.
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